Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | May 24, 2017 | May 25, 2017 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director · CHAIRMAN & CEO | September 01, 2026 | September 03, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 08, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 24, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2027-05-24 | Direct | 30,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning June 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning June 24, 2017.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 86,165 |
Reported balance
After 2026-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 9,991 · Balance 86,165 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,646 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Acquired 6,481 · Balance 92,646 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 98,883 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Acquired 6,237 · Balance 98,883 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 107,492 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Exercise / conversion · Acquired 8,609 · Balance 107,492 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,348 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Tax withholding · Disposed 15,144 · Balance 92,348 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 30,050 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 30,050 · Balance 30,050 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 25,826 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 8,609 · Balance 25,826 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 12,475 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 6,237 · Balance 12,475 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,481 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 6,481 · Balance 6,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 9,991 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 120,150 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 120,150 · Balance 120,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | 109,795 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 109,795 |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | 51,794 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 51,794 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Syros Pharmaceuticals, Inc.
Report date June 08, 2017 · Filed September 22, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2027-06-07 | Direct | 11,000 |
Reported balance
After 2017-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 11,000 · Balance 11,000 F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.
F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 101 | $27.00 | $2,727.00 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 101 | $1.59 | $160.59 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 1,965 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,621 Underlying: Class A Ordinary Share · 1,965 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,965 | $27.00 | $53,055.00 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.03 and $27.14. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,965 | $1.59 | $3,124.35 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 13,328 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,238 Underlying: Class A Ordinary Share · 13,328 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 12,910 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,910 Underlying: Class A Ordinary Share · 12,910 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 8,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,386 Underlying: Class A Ordinary Share · 8,386 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 7,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,987 Underlying: Class A Ordinary Share · 7,987 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010482 · form4-04092025_080409.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,991 Underlying: Class A Ordinary Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,832 | $20.28 | $97,992.96 |
DisclosureSEC source: 0001415889-25-010482 · form4-04092025_080409.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,674 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010482 · form4-04092025_080409.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,712 Underlying: Class A Ordinary Share · 6,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,962 Underlying: Class A Ordinary Share · 6,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 68,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,869 Underlying: Class A Ordinary Share · 68,869 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 34,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,435 Underlying: Class A Ordinary Share · 34,435 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 137,638 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,638 Underlying: Class A Ordinary Share · 137,638 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 3,017 | $21.77 | $65,680.09 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,514 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,304 | $21.77 | $50,158.08 |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,531 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009993 · form4-04032025_090418.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008614 · form4-03192025_090332.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,004 | $22.61 | $45,310.44 |
DisclosureSEC source: 0001415889-25-008614 · form4-03192025_090332.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,116 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008614 · form4-03192025_090332.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 89,561 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-026451 · form4-11082024_091109.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,025 Underlying: Class A Ordinary Share · 89,561 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 89,561 | $23.00 | $2,059,903.00 |
DisclosureSEC source: 0001415889-24-026451 · form4-11082024_091109.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,551 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $23.00 and $23.12. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 89,561 | $1.59 | $142,401.99 |
DisclosureSEC source: 0001415889-24-026451 · form4-11082024_091109.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,569 Underlying: Class A Ordinary Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 3,177 | $26.74 | $84,952.98 |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,551 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,443 Underlying: Class A Ordinary Share · 6,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,983 Underlying: Class A Ordinary Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 129,750 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,750 Underlying: Class A Ordinary Share · 129,750 shares Expires 2034-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 24,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,950 Underlying: Class A Ordinary Share · 24,950 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 7,967 | $26.74 | $213,037.58 |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,159 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:55 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 16,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022857 · form4-09052024_120917.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 136,124 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-020108 · form4-07252024_080727.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,147 Underlying: Class A Ordinary Share · 136,124 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 63,049 | $27.01 | $1,702,953.49 |
DisclosureSEC source: 0001415889-24-020108 · form4-07252024_080727.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,012 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.07. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 50,000 | $25.05 | $1,252,500.00 |
DisclosureSEC source: 0001415889-24-020108 · form4-07252024_080727.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,061 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.00 and $25.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 23,075 | $23.25 | $536,493.75 |
DisclosureSEC source: 0001415889-24-020108 · form4-07252024_080727.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,061 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 136,124 | $1.59 | $216,437.16 |
DisclosureSEC source: 0001415889-24-020108 · form4-07252024_080727.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,401 Underlying: Class A Common Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 4,075 | $17.90 | $72,942.50 |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,012 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 24,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,393 Underlying: Class A Common Share · 24,950 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Share · 20,000 shares Expires 2034-03-31 F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 129,750 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010514 · form4-04082024_090415.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,750 Underlying: Class A Common Share · 129,750 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010086 · form4-04032024_090440.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,443 Underlying: Class A Common Share · 6,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,903 | $19.70 | $37,489.10 |
DisclosureSEC source: 0001415889-24-010086 · form4-04032024_090440.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,095 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 6,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010086 · form4-04032024_090440.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.